Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents.

ABSTRACT: ADCs have emerged as a promising class of therapeutics, combining the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Although the majority of approved ADCs are still based on microtubule binder payloads, the recent success of topoisomerase I inhibitors has revitalized interest in the identification of novel agents overcoming present limitations in the field including narrow therapeutic window and chemoresistance. The success of DNA binders as payload for ADCs has been very limited, up to now, due, among other factors, to high hydrophobicity and planar chemical structures resulting in most cases in ADCs with a strong tendency to aggregate, poor plasma stability, and limited therapeutic index. Some of these molecules, however, continue to b

SUBMITTER: Valsasina B 

PROVIDER: S-EPMC11510327 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature